MandalMed, Inc is an innovative and privately-held company specializing in the modulation of glycobiology and innate immunity. Inspired by the ancient symbol of wholeness and unity, the company is driven to develop cutting-edge treatments for organ fibrosis. Their primary focus is on galectin-3, a carbohydrate binding protein associated with fibrosis.

MandalMed's lead product, MM-003, is a protein inhibitor specifically designed to prevent and reverse fibrosis after myocardial infarction and in heart failure. The company is led by an exceptional team, including President and CEO, Dr. Constance M.

John. Dr. John is also an Adjunct Associate Professor of Laboratory Medicine at the University of California, San Francisco.

The team also includes VP of Product Development, Dr. Khalid Mounzih, who brings a wealth of experience from renowned biotech companies. MandalMed also benefits from their partnerships with esteemed service providers, such as Dr.

Catherine Polizzi of Morrison & Foerster, a leading IP practice, and Mr. Gregory Porter of Silverman, Krantz, & Porter, a trusted accounting firm. With their unwavering dedication to medical advancements and a commitment to quality, MandalMed is at the forefront of developing groundbreaking solutions for fibrosis.

Contact them today to learn more about their remarkable work